New opportunities for industrial biotechnology companies
i3 is attracting interest as a potential site for emerging industrial biotechnology companies.
The large, flat, serviced plots available for development at i3 are widely recognised as ideal investment opportunities for a range of businesses, but the existing interests of companies in the area mean this site is well placed to be considered by those in this rapidly developing industrial biotechnology sector.
Recently the European Forum of Industrial Biotechnology held its annual conference in Glasgow and delegates were able to discover some of the sites and opportunities that currently exist in Scotland. IBioIC, an innovation centre launched in 2014, played an important part in bringing the event to Scotland.
Irvine Bay is one of 3 Industrial Biotechnology locations featured by SDI alongside Grangemouth and Guardbridge in Fife to highlight the specific opportunities for this sector currently available in Scotland.
Commenting on the opportunities earlier this year, Patrick Wiggins, CEO, said, "Industries are increasingly looking to biotechnology to improve the manufacture of products to achieve a number of aims, such as reduced carbon footprint; improved recyclability; better use of sustainable raw materials; and reduced reliance on heavy and precious metals as catalysts." Read more about how industrial biotechnology is driving sustainable change.
At i3, Irvine's Enterprise Area, there are already premises under construction including factory, office, and specialist pharmaceutical facilities. As a centre for life sciences and manufacturing, the area has a long history, but recent developments have focussed this reputation into creating new investments.
Much of i3 is designated as an Enterprise Area, meaning that there are tax incentives and other supports available to companies choosing to relocated. The main focus for the Enterprise Area is life sciences and this would include many industrial biotechnology projects.
New companies are moving into the enterprise area and jobs are being created. Betweem 2012 and 2015 over 400 jobs were created in i3, representing tremendous growth for the venture. Over £100m of capital investment has been committed by the private sector, with new companies moving in and existing companies expanding.
GSK plays an important role as an anchor tenant at i3, and there are supply chain companies that have chosen to locate there as a result.